Katharina Bernhardt
Brigham and Women's Hospital
4 Papers
Katharina Bernhardt is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Biology & Epstein–Barr virus. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Katharina Bernhardt include Harvard University.
Chat about Author
Papers
Epstein-Barr Virus Oncoprotein Super-enhancers Control B Cell Growth
Hufeng Zhou,Hufeng Zhou,Stefanie C.S. Schmidt,Stefanie C.S. Schmidt,Sizun Jiang,Sizun Jiang,Bradford Willox,Katharina Bernhardt,Katharina Bernhardt,Jun Liang,Jun Liang,Eric Johannsen,Peter V. Kharchenko,Benjamin E. Gewurz,Benjamin E. Gewurz,Elliott Kieff,Elliott Kieff,Bo Zhao,Bo Zhao +18 more
TL;DR: In insight into mechanisms of EBV-induced lymphoproliferation and potential therapeutic interventions, EBV super-enhancer-associated genes included the MYC and BCL2 oncogenes, which enable LCL proliferation and survival are provided.
179
TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation
Hannah Greenfeld,Kaoru Takasaki,Michael J. Walsh,Ina Ersing,Katharina Bernhardt,Yijie Ma,Bishi Fu,Camille W. Ashbaugh,Jackson Cabo,Sarah B. Mollo,Hufeng Zhou,Shitao Li,Benjamin E. Gewurz +12 more
TL;DR: It is found that LMP1 TES1 domain signaling induced an association between TRAF1 and the linear ubiquitin chain assembly complex (LUBAC), and stimulated linear (M1)-linked polyubiquitin chains attachment to TRAf1 complexes, highlighting LUBAC as a novel potential therapeutic target in EBV-associated lymphoproliferative disorders.
NF-κB and IRF7 pathway activation by Epstein-Barr virus Latent Membrane Protein 1.
TL;DR: The principal Epstein-Barr virus oncoprotein, Latent Membrane Protein 1, is expressed in most EBV-associated human malignancies and its function is reviewed, with special attention to current understanding of the molecular mechanisms of LMP1-mediated NF-κB and IRF7 pathway activation.
CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors
Yijie Ma,Michael J. Walsh,Katharina Bernhardt,Camille W. Ashbaugh,Stephen J. Trudeau,Isabelle Y. Ashbaugh,Sizun Jiang,Sizun Jiang,Chang Jiang,Bo Zhao,David E. Root,John G. Doench,Benjamin E. Gewurz,Benjamin E. Gewurz,Benjamin E. Gewurz +14 more
TL;DR: This systematic approach uncovered key mechanisms by which EBV oncoproteins activate the PI3K/AKT pathway and evade tumor suppressor responses, and identifies viral transformation-driven synthetic lethal targets for therapeutic intervention.